Santen Pharmaceutical: 21 fiscal years of results, 2006–2026
- Revenue · FYE Mar 2026
- ¥292bn
- Operating profit · FYE Mar 2026
- ¥48bn
- Net profit · FYE Mar 2026
- ¥37bn
- Total assets
- ¥423bn
- Equity ratio
- 70.4%
- Fiscal years on record
- 21 · 2006–2026
This page carries 21 fiscal years of results, from 2006 to 2026. Revenue peaked in 2024 and has not returned to that level since. The company reported a net loss in one year: 2023.
| Fiscal year | Unit | 2006 FYE Mar | 2007 FYE Mar | 2008 FYE Mar | 2009 FYE Mar | 2010 FYE Mar | 2011 FYE Mar | 2012 FYE Mar | 2013 FYE Mar | 2014 FYE Mar | 2015 FYE Mar | 2016 FYE Mar | 2017 FYE Mar | 2018 FYE Mar | 2019 FYE Mar | 2020 FYE Mar | 2021 FYE Mar | 2022 FYE Mar | 2023 FYE Mar | 2024 FYE Mar | 2025 FYE Mar | 2026 FYE Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | JPY | ¥98bn | ¥101bn | ¥103bn | ¥102bn | ¥111bn | ¥111bn | ¥114bn | ¥119bn | ¥149bn | ¥162bn | ¥195bn | ¥199bn | ¥225bn | ¥234bn | ¥242bn | ¥250bn | ¥266bn | ¥279bn | ¥302bn | ¥300bn | ¥292bn |
| YoY | % | — | +2.1% | +2.9% | -1.7% | +8.9% | +0.2% | +3.2% | +4.1% | +24.9% | +8.8% | +20.7% | +1.9% | +13.0% | +4.0% | +3.2% | +3.3% | +6.7% | +4.8% | +8.2% | -0.7% | -2.8% |
| Operating profit | JPY | — | — | — | — | — | — | — | — | — | ¥35bn | — | — | ¥39bn | ¥45bn | ¥34bn | ¥12bn | ¥36bn | -¥3.1bn | ¥39bn | ¥47bn | ¥48bn |
| YoY | % | — | — | — | — | — | — | — | — | — | — | — | — | — | +16.5% | -25.7% | -63.6% | +194.3% | -108.6% | — | +21.8% | +1.9% |
| Ordinary profit | JPY | ¥22bn | ¥21bn | ¥21bn | ¥16bn | ¥30bn | ¥32bn | ¥28bn | ¥26bn | ¥28bn | — | — | — | — | — | — | — | — | — | — | — | — |
| Net profit | JPY | ¥13bn | ¥13bn | ¥13bn | ¥10bn | ¥19bn | ¥21bn | ¥17bn | ¥17bn | ¥17bn | ¥24bn | ¥53bn | ¥22bn | ¥35bn | ¥32bn | ¥24bn | ¥9.3bn | ¥27bn | -¥15bn | ¥27bn | ¥36bn | ¥37bn |
| YoY | % | — | +0.8% | -3.8% | -19.8% | +85.1% | +13.9% | -19.2% | -4.1% | +3.6% | +40.4% | +122.5% | -59.4% | +62.2% | -9.1% | -26.2% | -60.6% | +192.5% | -154.8% | — | +36.5% | +3.0% |
| Operating margin | % | — | — | — | — | — | — | — | — | — | 21.9% | — | — | 17.2% | 19.3% | 13.9% | 4.9% | 13.5% | -1.1% | 12.7% | 15.6% | 16.4% |
| Net margin | % | 13.2% | 13.0% | 12.2% | 9.9% | 16.9% | 19.2% | 15.0% | 13.9% | 11.5% | 14.8% | 27.3% | 10.9% | 15.7% | 13.7% | 9.8% | 3.7% | 10.2% | -5.3% | 8.8% | 12.1% | 12.8% |
| Standard | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | IFRS | |
| Basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Where each yen of revenue goes — cost of sales, SG&A and what is left as operating profit (¥ bn, stacked)
| Fiscal year | Unit | 2018 *1 FYE Mar | 2019 *1 FYE Mar | 2020 *1 FYE Mar | 2021 *1 FYE Mar | 2022 *1 FYE Mar | 2023 *1 FYE Mar | 2024 *1 FYE Mar | 2025 *1 FYE Mar | 2026 *1 FYE Mar |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | JPY | ¥225bn | ¥234bn | ¥242bn | ¥250bn | ¥266bn | ¥279bn | ¥302bn | ¥300bn | ¥292bn |
| YoY | % | — | +4.0% | +3.2% | +3.3% | +6.7% | +4.8% | +8.2% | -0.6% | -2.8% |
| Cost of sales | JPY | ¥86bn | ¥91bn | ¥95bn | ¥98bn | ¥110bn | ¥113bn | ¥123bn | ¥129bn | ¥122bn |
| SG&A | JPY | ¥69bn | ¥71bn | ¥73bn | ¥80bn | ¥84bn | ¥96bn | ¥92bn | ¥88bn | ¥90bn |
| Other operating costs | JPY | — | — | — | — | — | ¥73bn | ¥48bn | — | — |
| Operating profit | JPY | ¥39bn | ¥45bn | ¥34bn | ¥12bn | ¥36bn | -¥3.1bn | ¥39bn | ¥47bn | ¥48bn |
| YoY | % | — | +16.6% | -25.6% | -63.7% | +194.5% | -108.6% | — | +21.6% | +2.0% |
| Operating margin | % | 17.2% | 19.3% | 13.9% | 4.9% | 13.5% | -1.1% | 12.8% | 15.6% | 16.4% |
| Change | pp | — | +2.1pp | -5.4pp | -9.0pp | +8.6pp | -14.6pp | +13.9pp | +2.8pp | +0.8pp |
- *1 Securities report (yuka shoken hokokusho), as filed
Total assets, equity and interest-bearing debt (¥ bn), with the equity ratio (%)
| Fiscal year | Unit | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Mar | 2017 *1 FYE Mar | 2018 *1 FYE Mar | 2019 *1 FYE Mar | 2020 *1 FYE Mar | 2021 *1 FYE Mar | 2022 *1 FYE Mar | 2023 *1 FYE Mar | 2024 *1 FYE Mar | 2025 *1 FYE Mar | 2026 *1 FYE Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | JPY | ¥199bn | ¥200bn | ¥231bn | ¥296bn | ¥355bn | ¥359bn | ¥388bn | ¥391bn | ¥409bn | ¥405bn | ¥460bn | ¥421bn | ¥436bn | ¥409bn | ¥423bn |
| YoY | % | — | +0.4% | +15.8% | +28.2% | +19.9% | +1.0% | +8.2% | +0.7% | +4.5% | -0.9% | +13.5% | -8.4% | +3.4% | -6.1% | +3.4% |
| Equity | JPY | ¥165bn | ¥165bn | ¥181bn | ¥205bn | ¥260bn | ¥255bn | ¥284bn | ¥289bn | ¥303bn | ¥311bn | ¥338bn | ¥295bn | ¥307bn | ¥287bn | ¥298bn |
| YoY | % | — | +0.2% | +9.7% | +13.0% | +27.0% | -1.9% | +11.4% | +1.8% | +4.8% | +2.5% | +8.8% | -12.9% | +4.1% | -6.3% | +3.7% |
| Equity ratio | % | 82.9% | 82.7% | 78.4% | 69.1% | 73.2% | 71.1% | 73.1% | 73.9% | 74.2% | 76.7% | 73.5% | 70.0% | 70.4% | 70.2% | 70.4% |
| Change | pp | — | -0.2pp | -4.3pp | -9.3pp | +4.1pp | -2.1pp | +2.0pp | +0.8pp | +0.3pp | +2.5pp | -3.2pp | -3.5pp | +0.4pp | -0.2pp | +0.2pp |
- *1 Securities report (yuka shoken hokokusho), as filed
Cash generated by operations, spent on investment and raised or repaid in financing (¥ bn)
| Fiscal year | Unit | 2006 *1 FYE Mar | 2007 *1 FYE Mar | 2008 *1 FYE Mar | 2009 *1 FYE Mar | 2010 *1 FYE Mar | 2011 *1 FYE Mar | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Mar | 2017 *1 FYE Mar | 2018 *1 FYE Mar | 2019 *1 FYE Mar | 2020 *1 FYE Mar | 2021 *1 FYE Mar | 2022 *1 FYE Mar | 2023 *1 FYE Mar | 2024 *1 FYE Mar | 2025 *1 FYE Mar | 2026 *1 FYE Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | JPY | ¥21bn | ¥15bn | ¥15bn | ¥12bn | ¥26bn | ¥18bn | ¥21bn | ¥9.9bn | ¥26bn | ¥25bn | ¥23bn | ¥11bn | ¥43bn | ¥33bn | ¥40bn | ¥39bn | ¥46bn | ¥37bn | ¥73bn | ¥61bn | ¥44bn |
| YoY | % | — | -28.4% | +3.4% | -23.4% | +120.4% | -31.9% | +20.9% | -53.7% | +161.1% | -4.6% | -9.0% | -51.9% | +295.1% | -23.2% | +21.4% | -2.9% | +18.6% | -19.3% | +95.6% | -16.1% | -28.6% |
| Investing CF | JPY | -¥1.3bn | -¥5.8bn | -¥2.1bn | -¥5.6bn | -¥0.8bn | -¥7.7bn | -¥10bn | -¥4.6bn | -¥6.7bn | -¥61bn | ¥37bn | -¥28bn | -¥8.3bn | -¥2.9bn | -¥5.2bn | -¥53bn | -¥35bn | -¥27bn | -¥6.1bn | -¥8.2bn | -¥13bn |
| Financing CF | JPY | -¥5.9bn | -¥5.7bn | -¥11bn | -¥11bn | -¥6.8bn | -¥1.6bn | -¥8.6bn | -¥22bn | -¥8.0bn | ¥29bn | -¥24bn | -¥29bn | -¥18bn | -¥28bn | -¥13bn | -¥17bn | ¥5.6bn | -¥37bn | -¥34bn | -¥53bn | -¥49bn |
| Cash & equivalents | JPY | ¥46bn | ¥50bn | ¥52bn | ¥46bn | ¥64bn | ¥72bn | ¥75bn | ¥60bn | ¥72bn | ¥66bn | ¥100bn | ¥52bn | ¥69bn | ¥71bn | ¥91bn | ¥63bn | ¥83bn | ¥58bn | ¥95bn | ¥93bn | ¥81bn |
| YoY | % | — | +8.1% | +3.7% | -11.1% | +40.0% | +12.6% | +3.5% | -20.3% | +21.1% | -8.9% | +51.4% | -47.6% | +32.5% | +2.2% | +29.1% | -31.2% | +32.0% | -30.2% | +63.3% | -1.7% | -13.0% |
- *1 Securities report (yuka shoken hokokusho), as filed
Profitability and balance-sheet strength (%). ROE uses year-end equity.
| Fiscal year | Unit | 2006 *1 FYE Mar | 2007 *1 FYE Mar | 2008 *1 FYE Mar | 2009 *1 FYE Mar | 2010 *1 FYE Mar | 2011 *1 FYE Mar | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Mar | 2017 *1 FYE Mar | 2018 *1 FYE Mar | 2019 *1 FYE Mar | 2020 *1 FYE Mar | 2021 *1 FYE Mar | 2022 *1 FYE Mar | 2023 *1 FYE Mar | 2024 *1 FYE Mar | 2025 *1 FYE Mar | 2026 *1 FYE Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | % | — | — | — | — | — | — | — | — | — | — | — | — | 17.2% | 19.3% | 13.9% | 4.9% | 13.5% | -1.1% | 12.8% | 15.6% | 16.4% |
| Change | pp | — | — | — | — | — | — | — | — | — | — | — | — | — | +2.1pp | -5.4pp | -9.0pp | +8.6pp | -14.6pp | +13.9pp | +2.8pp | +0.8pp |
| Net margin | % | 13.2% | 13.1% | 12.2% | 10.0% | 16.9% | 19.3% | 15.0% | 13.9% | 11.5% | 13.9% | 27.3% | 10.9% | 15.7% | 13.7% | 9.8% | 3.7% | 10.2% | -5.4% | 8.8% | 12.1% | 12.8% |
| Change | pp | — | -0.1pp | -0.9pp | -2.2pp | +6.9pp | +2.4pp | -4.3pp | -1.1pp | -2.4pp | +2.4pp | +13.4pp | -16.4pp | +4.8pp | -2.0pp | -3.9pp | -6.1pp | +6.5pp | -15.6pp | +14.2pp | +3.3pp | +0.7pp |
| ROE | % | — | — | — | — | — | — | 10.4% | 10.0% | 9.4% | 11.0% | 20.5% | 8.5% | 12.4% | 11.0% | 7.8% | 3.0% | 8.0% | -5.1% | 8.7% | 12.6% | 12.5% |
| Change | pp | — | — | — | — | — | — | — | -0.4pp | -0.6pp | +1.6pp | +9.5pp | -12.0pp | +3.9pp | -1.4pp | -3.2pp | -4.8pp | +5.0pp | -13.1pp | +13.8pp | +3.9pp | -0.1pp |
| Equity ratio | % | — | — | — | — | — | — | 82.9% | 82.7% | 78.4% | 69.1% | 73.2% | 71.1% | 73.1% | 73.9% | 74.2% | 76.7% | 73.5% | 70.0% | 70.4% | 70.2% | 70.4% |
| Change | pp | — | — | — | — | — | — | — | -0.2pp | -4.3pp | -9.3pp | +4.1pp | -2.1pp | +2.0pp | +0.8pp | +0.3pp | +2.5pp | -3.2pp | -3.5pp | +0.4pp | -0.2pp | +0.2pp |
- *1 Securities report (yuka shoken hokokusho), as filed
The revenue line above, converted at the average ¥/US$ rate of each figure’s own year — never today’s.
Between 2006–2026, Santen Pharmaceutical’s revenue grew 3.0-fold in yen (5.6% a year). Converted at each year’s own average rate, the same span is 2.2-fold in dollars (4.0% a year), from $846m to $1.8bn. The dollar figure grew more slowly because the yen weakened over the period: part of the growth an investor sees in yen does not survive translation into dollars.
| Fiscal year | Unit | 2006 *4 FYE Mar | 2007 *4 FYE Mar | 2008 *4 FYE Mar | 2009 *4 FYE Mar | 2010 *4 FYE Mar | 2011 *4 FYE Mar | 2012 *4 FYE Mar | 2013 *4 FYE Mar | 2014 *4 FYE Mar | 2015 *4 FYE Mar | 2016 *4 FYE Mar | 2017 *4 FYE Mar | 2018 *4 FYE Mar | 2019 *4 FYE Mar | 2020 *4 FYE Mar | 2021 *4 FYE Mar | 2022 *4 FYE Mar | 2023 *4 FYE Mar | 2024 *4 FYE Mar | 2025 *4 FYE Mar | 2026 *4,5 FYE Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | USD | $846m | $853m | $1.0bn | $1.1bn | $1.3bn | $1.4bn | $1.4bn | $1.2bn | $1.4bn | $1.3bn | $1.8bn | $1.8bn | $2.0bn | $2.1bn | $2.3bn | $2.3bn | $2.0bn | $2.0bn | $2.0bn | $2.0bn | $1.8bn |
| YoY | % | — | +0.8% | +17.3% | +8.6% | +16.0% | +10.2% | +3.2% | -14.9% | +15.1% | -4.8% | +34.2% | -1.1% | +14.8% | +5.4% | +5.4% | +0.5% | -10.8% | -2.0% | +0.4% | +0.6% | -8.0% |
| Revenue as filed | JPY | ¥98bn | ¥101bn | ¥103bn | ¥102bn | ¥111bn | ¥111bn | ¥114bn | ¥119bn | ¥149bn | ¥162bn | ¥195bn | ¥199bn | ¥225bn | ¥234bn | ¥242bn | ¥250bn | ¥266bn | ¥279bn | ¥302bn | ¥300bn | ¥292bn |
| Rate applied | ¥/US$ | ¥116.28 | ¥117.77 | ¥103.33 | ¥93.53 | ¥87.77 | ¥79.78 | ¥79.79 | ¥97.60 | ¥105.84 | ¥121.02 | ¥108.84 | ¥112.16 | ¥110.40 | ¥109.01 | ¥106.78 | ¥109.78 | ¥131.37 | ¥140.51 | ¥151.50 | ¥149.65 | ¥158.16 |
- *1 1949-1971: Fixed Bretton Woods peg ¥360/$ (Dodge Line 1949; Smithsonian ¥308 from Dec 1971).
- *2 1972: Smithsonian peg ¥308/$ (held until Feb 1973 float).
- *3 1973-1979: JIL (Japan Institute for Labour Policy and Training) g0001.xlsx — fiscal-year (Apr–Mar) basis, integer-rounded. PROVISIONAL; upgrade to BOJ FXERM07 calendar-year later.
- *4 1980-2026: Bank of Japan stat-search FM08'FXERM07 (Tokyo market, USD/JPY spot, 17:00 fixing, monthly average) — calendar-year average of monthly averages.
- *5 Provisional — part-year average, not a full calendar year.
Which accounting standard each stretch of the series was filed under, and whether the accounts are consolidated.
The series crosses 2 reporting regimes — consolidated Japanese GAAP for 2006–2014; and consolidated IFRS for 2015–2026. Figures are not strictly comparable across a change of basis: consolidation in particular adds subsidiaries that were previously outside the accounts.
| Fiscal years | Standard | Basis | Years |
|---|---|---|---|
| 2006–2014 | Japanese GAAP | consolidated | 9 |
| 2015–2026 | IFRS | consolidated | 12 |
All figures are in Japanese yen as filed. Where a foreign-currency comparison is needed elsewhere on this site, yen amounts are converted at the average rate of each figure's own year — not today's rate. Exchange rates & sources →
Read the company history → 日本語版（詳細）— full financial data in Japanese →
Data API
Santen Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
/api/4536/manifest.json ·/api/4536/history.json ·/api/4536/timeline.json ·/api/4536/decisions.json ·/api/4536/executives.json ·/api/4536/shareholders.json ·/api/4536/financials.json ·/api/4536/financials-longterm.json ·/api/4536/segments.json ·/api/4536/regions.json ·/api/4536/workforce.json · /api/4536/decisions/{slug}.json